We describe an ultrafiltration technique for rapidly and directly determining free triiodothyronine or free thyroxine, or both. After equilibrating serum at 37 #{176}C with purified tracer ofhighspecific activity, we placed0.15mL of serum in 2.8 mL of phosphate buffer (0.1 mauL, pH 7.4) in the ultrafiltration cell and obtained successive 0.2-and 0.6-mL fractions of protein-free ultrafiltrate. Under our conditions free ligand concentration was independent of flow rate. Afterpurifying the second fraction with protein-coated charcoal, we could determine the proportion of free tniodothyronine or free thyroxine. Samplesfromnormaladult men and women, including women who were taking oral contraceptives or were pregnant, and fromhypo-and hyperthyroid patients gave results thatagreed withthose obtainedby equilibrium dialysis. Speed is the main advantage of the method: one technologist can complete the procedure in 2 h and, using a multi-micro-ultrafiltration system, can process many samples in one day. For laboratories where index-type reactions are performed routinely and direct free triiodothyronine or free thyroxine is determined only on selected specimens, this method is superior to dialysis. It is also very convenient for rapidly purifying tracers, to at least 97% radiochemical purity, with 94% recovery and no dilution.
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We describe the accurate, rapid, and convenient determination of free triiodothyronine (FT3)3 and free thyroxine (FT4) of diluted serum by a simplified ultrafiltration method. The accuracy of ultrafiltration and its theoretical equivalence to equilibrium dialysis were shown previously by Sophianopoulos et al. (1) . We confirm the usefulness of the method of comparing results obtained for FT3 and FT4 by ultrafiltration with those obtained by equilibrium dialysis of diluted serum, generally accepted to be the best clinical method for FT3 and FT4 (2) . Previously published ultrafiltration methods (3-5) and other techniques (6) (7) (8) (9) (10) (11) (12) (13) are time consuming and require considerable amount of manipulation.
Tracer Purification
Triiodothyronine labeled with 1251 (T3 tracer) and L-thyroxine labeled with 125J (T4 tracer), both with a listed specific radioactivity of 1200 Ci/g, were obtained from Amershani Corporation, Arlington Heights, IL 60005. We checked the radiochemical purity by mixing an aliquot of the tracer with markers, i.e., tyrosine, T3, and T4 (all from Sigma Chemical Co., St. Louis, MO 63178). We chromatographed the sample on thin-layer Silica Gel G precoated glass plates in the solvent system of acetone/tert-amyl alcohol/NH4OH (1 mol/L), 3/1/1, by vol, and used Rhodamine G spray to reveal the position of the markers. By dividing the chromatogram into sections parallel to the solvent front, scraping each section from the glass plate into a vial, and counting the radioactivity, we were able to compare the distribution of radioactivity and of the chemical components.
Both tracers required purification before use, to remove inorganic 125!. The traditional method of purifying T3 and T4 tracers is to dialyze serum-bound tracer against pH 7.4 Sorensen buffer (14) . We use ultrafiltration to purify T3 and T4 tracers, and achieve the same degree of purification in only 1 h, as follows: Evaporate 0.1 mL of crude T4 tracer solution under nitrogen. Add 1 mL of hormone-free serum (14) , vortex-mix briefly, and incubate for 30 mm at 25 #{176}C in the dark. Add 1 mL of phosphate buffer (100 mmol/L, pH 7.4). Ultrafilter the solution at 4 #{176}C for 25 mm, and discard the 1-mL ultrafiltrate; add 1 mL of phosphate buffer to the solution of tracer and serum, and ultrafilter for an additional 25 mm at 4 #{176}C. Save the serum solution, and discard the 1-mL ultraf'iltrate. T3 tracer is easier to purify. One ultrafiltration for only 30 mm was sufficient to achieve the same degree of purity as dialysis for 24 h. Except for the time required, use the same procedure to ultrafilter T. tracer as was described for T4 tracer.
Total13 and 14
Serum total T3 concentration was measured by radioimmunoassay (RIA) according to Twomey and Sweat (15) . Serum total T4 concentration was determined by RIA with a specific anti-T4 antibody and precipitation of the T4-antibody complex by polyethylene glycol in a fashion similar to that for total T3 (15).
Equilibrium
Dialysis T3 and T4 tracers were prepurified by dialysis according to Schussler and Plager (14) . FT3 and FT4 concentrations were determined by the equilibrium dialysis technique of Wilson
etal. (2).

Apparatus
We use a micro-volume stirred ultrafiltration cell, 3-mL capacity (Model 3; Amicon Corporation, Lexington, MA 02173) with 25 mm Diaflo YM-lO membrane, also from Amicon, which has a relative molecular mass (Mr) cut-off of 10 000 daltons ± 3%. The membrane should be washed before its first use by soaking for at least 1 h in de-ionized water. Change the water four times, allowing the membrane to soak for 15 mm each time. After the last soak period, blot the membrane for a few seconds, and locate the shinier side by holding the membrane under a tungsten lamp, with all fluorescent light turned off. This side is the one that should contact the serum solution. Place the membrane in its compartment and assemble the ultrafiltration cell as described in the manufacturer's instructions.
After ultrafiltration, withdraw the remaining serum solution from the cell, and wash the cell and membrane four times while the cell is still assembled. For each wash, add de-ionized water, stir for 308, then ultrafilter for 3 mm and withdraw the wash water from the cell. This washing procedure reduces to background level the radioactivity inside the cell and in the ultrafiltrate.
We have on occasion used a single membrane for more than a dozen assays, but we recommend changing the membrane after about three or four assays to minimize the possibility of tearing it.
Procedure
FT3 assay. Mix gently and thoroughly 4.75 mL of phosphate buffer (100 mmol/L, pH 7.4), 0.25 mL of serum sample, and 0.1 mL of purified T3 tracer in a 20-mL glass scintillation vial. Incubate the resulting solution for 30 mm at 37 #{176}C. Pipet duplicate 0.5-mL aliquots for "total counts" into two polystyrene tubes and pipet 3.0 mL into the ultrafiltration cell. Place the cell on a magnetic stirrer (Model PC-353; Corning Glass Works, Corning, NY 14830). Begin sufficient stirring for thorough mixing without frothing. After 30 s, ultrafilter the solution under nitrogen pressure of 18 psig, with continuous stirring. Under these conditions, the flow rate is about 0.06 mL/min.
Collect two successive ultrafiltrates into the tubes, about 0.2 mL in the first tube and 0.6 to 0.8 mL in the weighed second tube. Discard the first ultrafiltrate, because it is diluted by the void volume (approximately 0.035 mL) of the membrane (1, 16) . The volume range stated for the second tube is sufficient to contain radioactive hormone with at least three times background cpm for patients with very low FT3. The ultrafiltration is complete in about 20 mm, 3 mm being sufficient for the first tube. Determine the volume of the second ultrafiltrate by weighing the second tube and its contents. Add 1 mL of KI solution (13.3 mmol/L) to the second tube, vortex-mix, add 0.5 mL of hemoglobin-coated charcoal suspension (2), and vortex-mix again. Incubate for 10 mm, then centrifuge for 5 mm at 2500 rpm, both at room temperature. Discard the supernatant liquid. Add 4 mL of working KI solution (13.3 mmol/L) to the charcoal pellet, vortex-mix, and centrifuge for 5 mm at 3000 rpm at room temperature. Again, discard the supernatant liquid. The function of the charcoal is to adsorb the T3 in the ultrafiltrate, leaving in the supernate any '251-labeled iodide. The K! solution serves as a "carrier" for '251-labeled iodide. This procedure is necessary in any assay for free thyroid hormones involving dialysis or its equivalent (2) .
Cap the total counts tubes and the tube containing the charcoal pellet, and place them in a gamma counter. Total counts are about 20 000 cpm; minimum counts in the pellet should be threefold the machine background. Total counting time is a little over 10 mm per assay.
FT4 assay. Use the same procedure as for the FT3 assay, except use 0.05 mL ofT4 tracer and 4.80 mL of buffer.
Calculations. Calculations for each assay require less than 5 mm, even if done by hand. % FT3 = (cpm of charcoal pellet/volume of contents of tube 2)(100) (average cpm of total counts tubes/0.5 mL)(20. 
Results
In preliminary experiments, not reported here, we failed to detect any protein (17) in the ultrafiltrates; this suggested to us that there was no protein leakage through the membrane. We also established by the following experiment the fact that the membrane and the whole apparatus in general did not adsorb tracer. A tracer amount of I-labeled T4 was dissolved in 100 mmol/L phosphate buffer (pH 7.4). After ultrafiltration (as described under Materials and Methods) the concentrations of radioactivity in the ultrafiltrate and inside the cell were found to be the same, indicating no adsorption of the unbound hormone.
Commercial lots of T3 and T4 tracer, upon receipt, contained approximately 100 mg of radioactive impurities per gram, mostly as '251-tabeled iodide. Tracer freshly purified by ultrafiltration or dialysis contained 25 mg of impurities per gram. Degradation of '251-labeled T4 is associated with an increase in %FT4 for all samples and high percentages of inorganic 1251-labelediodide (14) . In our hands, tracer purified by ultrafiltration and stored in a brown-glass bottle at 4 #{176}C was usable for two weeks: contamination with '25I-labeled iodide was less than 5% of total radioactivity. Repetitive use of such tracer (with less than 5% impurities) resulted in no significant increase in the %FT4 of pooled serum. The effect of serum dilution was studied next. We increasingly diluted serum with the phosphate buffer and measured VP4 (as described under Materials and Methods). The data (not shown here) indicated, in agreement with previous reports (2, 8, 20) , that with greater dilution the apparent FT4 concentration decreases steadily until it reaches a fixed amount (at approximately fivefold dilution). Intra-assay precision was 6.7% (coefficient of variation, CV), for 20 replicate assays of a serum pool with a mean value of 1.04 g/L of total T3. Interassay precision (CV) was 6.9% for 21 assays of the serum pool during a four-week period. Table 2 lists results of FT4 assays by ultrafiltration and equilibrium dialysis of 22 patients. The paired t-test indicates no significant difference (p <0.01) between the two methods. Regression analysis of FT4 values obtained by the two methods for 22 patients results in a slope of 0.94, a y-intercept of 0.01, and a correlation coefficient of 0.97 (Figure 2) .
Precision was evaluated from 20 analyses of two serum pools, with FT4 of 5.4 and 45 ng/L, respectively. Within-day variation for the pools was 6.2% and 6.7%, respectively; between-day variation during a period of four weeks was 6.5% and 6.9% for the low and high pools, respectively.
Discussion
Using The advantages of ultrafiltration are speed and convenience. Concentrations of FT3 and VF4 can be reported to the physician within less than 3 h after receiving a patient's serum.
Multi-cell arrangements are now available that enable one technologist to run six or eight simultaneous ultrafiltrations.
Final results for about 20 samples could, therefore, be ready in one day. The success of the method is a result of the recent commercial development of a suitable type of membrane. We tested many kinds of membranes, but only the Diaflo YM-lo fulfilled the requirements of no tracer adsorption, no protein leakage, and rapid ultrafiltration.
Increasing the volume of ultrafiltrate collected does not usually affect protein-binding equilibria (1) . Therefore, for patients with very low values of FT3 or FT4, the volume of ultrafiltrate collected may be increased to increase the number of counts obtained and thus decrease the counting error.
Ultrafiltration is also the method of choice for rapid tracer purification.
